↓ Skip to main content

Dove Medical Press

Role of collagenase clostridium histolyticum in Peyronie's disease

Overview of attention for article published in Biologics: Targets & Therapy, September 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
1 X user

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
44 Mendeley
Title
Role of collagenase clostridium histolyticum in Peyronie's disease
Published in
Biologics: Targets & Therapy, September 2015
DOI 10.2147/btt.s65619
Pubmed ID
Authors

Taylor C Peak, Gregory C Mitchell, Faysal A Yafi, Wayne J Hellstrom

Abstract

Peyronie's disease is a localized connective tissue disease characterized by an active, inflammatory phase and a stable, quiescent phase, with the eventual development of collagenous plaques within the tunica albuginea of the penis. Risk factors primarily associated with Peyronie's disease include Dupuytren's contracture, penile trauma, and family history. A variety of treatment strategies have been utilized, including oral and topical agents, electromotive drug administration, intralesional injections, extracorporeal shockwave therapy, penile traction, and surgery. However, most of these strategies are ineffective, with surgery being the only definitive treatment. Collagenase clostridium histolyticum is a newly US Food and Drug Administration-approved agent for intralesional injection. It is thought to downregulate many of the disease-related genes, cytokines, and growth factors and degrade collagen fibers. It also suppresses cell attachment, spreading, and proliferation. Collagenase clostridium histolyticum has been clinically proven to be a safe and effective therapeutic option, demonstrating decreases in penile curvature and plaque consistency, as well as increases in patient satisfaction. During clinical evaluation, the Peyronie's Disease Questionnaire was validated as an effective tool for assessing treatment outcomes.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 2%
Unknown 43 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 12 27%
Other 5 11%
Student > Bachelor 5 11%
Researcher 3 7%
Student > Postgraduate 3 7%
Other 7 16%
Unknown 9 20%
Readers by discipline Count As %
Medicine and Dentistry 22 50%
Biochemistry, Genetics and Molecular Biology 3 7%
Nursing and Health Professions 2 5%
Engineering 2 5%
Agricultural and Biological Sciences 1 2%
Other 0 0%
Unknown 14 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 April 2018.
All research outputs
#17,285,668
of 25,373,627 outputs
Outputs from Biologics: Targets & Therapy
#192
of 284 outputs
Outputs of similar age
#165,909
of 276,788 outputs
Outputs of similar age from Biologics: Targets & Therapy
#1
of 4 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 284 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 276,788 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them